{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:55:56Z","timestamp":1790207756206,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Cholangiocarcinoma (CCA) is a highly aggressive cancer that arises from the bile duct and has an extremely poor prognosis. Pemigatinib is the only Food and Drug Administration (FDA)-approved CCA-targeted drug. The CCA treatment options are insufficient considering its poor prognosis and increasing morbidity. Recently, Rho-associated coiled-coil containing protein kinase 2 (ROCK2) has been reported to promote resistance to chemotherapy. In this study, we investigated the role that ROCK2 plays in the development of resistance of CCA cells to Pemigatinib. Here, we developed Pemigatinib-resistant CCA cells, performed mRNA sequencing, retrieved The Cancer Genome Atlas (TCGA) data, and analysed ROCK2 expression in a large CCA cohort. The expression level of ROCK2 in CCA cells was significantly higher than that in adjacent noncancerous tissues. Increased expression of ROCK2 in CCA was related to a late TNM stage and decreased overall survival. Functional experiments revealed that downregulating the expression of ROCK2 promotes the ferroptosis of CCA cells, and enhances sensitivity to Pemigatinib. Moreover, upregulation of ROCK2 increased the expression of Drp1 protein. The effect of downregulating ROCK2 was reversed by Drp1 overexpression, and Drp1 knockdown inhibited Ferroptosis driven by ROCK2 overexpression. Mechanistically, ROCK2 stabilized the expression of Drp1 by competing with UBA52 to bind Drp1 and inhibiting the ubiquitination-mediated degradation of Drp1. Blocking of the UBA52\u2013 Drp1 axis inhibited the antitumour effect of Pemigatinib in ROCK2-knockdown cells both in vitro and in vivo. In conclusion, the ROCK2\/UBA52\/Drp1 axis is a pivotal driver of Pemigatinib resistance in CCA cells. These results provide novel insights into Pemigatinib resistance in CCA cells, suggesting that ROCK2 is a promising therapeutic target for the treatment of CCA.<\/jats:p>","DOI":"10.1038\/s41419-025-07804-9","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T19:10:00Z","timestamp":1751656200000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Targeting the ROCK2\/UBA52\/DRP1 axis enhances ferroptosis and overcomes pemigatinib resistance in Cholangiocarcinoma"],"prefix":"10.1038","volume":"16","author":[{"given":"Bolin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8305-1900","authenticated-orcid":false,"given":"Leifeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2253-1147","authenticated-orcid":false,"given":"Wei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,4]]},"reference":[{"key":"7804_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","volume":"7","author":"PJ Brindley","year":"2021","unstructured":"Brindley PJ, Bachini M, Ilyas SI, Khan SA, Loukas A, Sirica AE, et al. Cholangiocarcinoma. Nat Rev Dis Prim. 2021;7:65.","journal-title":"Nat Rev Dis Prim"},{"key":"7804_CR2","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nrgastro.2011.131","volume":"8","author":"B Blechacz","year":"2011","unstructured":"Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2011;8:512\u201322.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"7804_CR3","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.jhep.2014.01.021","volume":"60","author":"J Bridgewater","year":"2014","unstructured":"Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60:1268\u201389.","journal-title":"J Hepatol"},{"key":"7804_CR4","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21:671\u201384.","journal-title":"Lancet Oncol"},{"key":"7804_CR5","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41418-021-00897-7","volume":"29","author":"J Liu","year":"2022","unstructured":"Liu J, Ren G, Li K, Liu Z, Wang Y, Chen T, et al. The Smad4-MYO18A-PP1A complex regulates \u03b2-catenin phosphorylation and pemigatinib resistance by inhibiting PAK1 in cholangiocarcinoma. Cell Death Differ. 2022;29:818\u201331.","journal-title":"Cell Death Differ"},{"key":"7804_CR6","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1038\/s41388-022-02313-x","volume":"41","author":"Z Liu","year":"2022","unstructured":"Liu Z, Liu J, Chen T, Wang Y, Shi A, Li K, et al. Wnt-TCF7-SOX9 axis promotes cholangiocarcinoma proliferation and pemigatinib resistance in a FGF7-FGFR2 autocrine pathway. Oncogene. 2022;41:2885\u201396.","journal-title":"Oncogene"},{"key":"7804_CR7","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41571-024-00869-z","volume":"21","author":"M Katoh","year":"2024","unstructured":"Katoh M, Loriot Y, Brandi G, Tavolari S, Wainberg ZA, Katoh M. FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions. Nat Rev Clin Oncol. 2024;21:312\u201329.","journal-title":"Nat Rev Clin Oncol"},{"key":"7804_CR8","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X Jiang","year":"2021","unstructured":"Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22:266\u201382.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"7804_CR9","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s13238-020-00789-5","volume":"12","author":"P Koppula","year":"2021","unstructured":"Koppula P, Zhuang L, Gan B. Cystine transporter SLC7A11\/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell. 2021;12:599\u2013620.","journal-title":"Protein Cell"},{"key":"7804_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01479-z","volume":"22","author":"J Guo","year":"2024","unstructured":"Guo J, Wang S, Wan X, Liu X, Wang Z, Liang C, et al. Mitochondria-derived methylmalonic acid aggravates ischemia-reperfusion injury by activating reactive oxygen species-dependent ferroptosis. Cell Commun Signal. 2024;22:53.","journal-title":"Cell Commun Signal"},{"key":"7804_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.462","volume":"4","author":"Y Wang","year":"2023","unstructured":"Wang Y, Dai X, Li H, Jiang H, Zhou J, Zhang S, et al. The role of mitochondrial dynamics in disease. MedComm (2020). 2023;4:e462.","journal-title":"MedComm (2020)"},{"key":"7804_CR12","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1080\/15548627.2024.2319901","volume":"20","author":"X Chen","year":"2024","unstructured":"Chen X, Tsvetkov AS, Shen HM, Isidoro C, Ktistakis NT, Linkermann A, et al. International consensus guidelines for the definition, detection, and interpretation of autophagy-dependent ferroptosis. Autophagy. 2024;20:1213\u201346.","journal-title":"Autophagy"},{"key":"7804_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06045-y","volume":"14","author":"Y Liu","year":"2023","unstructured":"Liu Y, Lu S, Wu LL, Yang L, Yang L, Wang J. The diversified role of mitochondria in ferroptosis in cancer. Cell Death Dis. 2023;14:519.","journal-title":"Cell Death Dis"},{"key":"7804_CR14","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1016\/j.devcel.2024.09.004","volume":"59","author":"J Khatun","year":"2024","unstructured":"Khatun J, Gelles JD, Chipuk JE. Dynamic death decisions: How mitochondrial dynamics shape cellular commitment to apoptosis and ferroptosis. Dev Cell. 2024;59:2549\u201365.","journal-title":"Dev Cell"},{"key":"7804_CR15","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1146\/annurev-med-051914-022120","volume":"67","author":"AB Pernis","year":"2016","unstructured":"Pernis AB, Ricker E, Weng CH, Rozo C, Yi W. Rho kinases in autoimmune diseases. Annu Rev Med. 2016;67:355\u201374.","journal-title":"Annu Rev Med"},{"key":"7804_CR16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.tips.2010.12.006","volume":"32","author":"Q Zhou","year":"2011","unstructured":"Zhou Q, Gensch C, Liao JK. Rho-associated coiled-coil-forming kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular disease. Trends Pharmacol Sci. 2011;32:167\u201373.","journal-title":"Trends Pharmacol Sci"},{"key":"7804_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100604","volume":"5","author":"MML Lei","year":"2023","unstructured":"Lei MML, Leung CON, Lau EYT, Leung RWH, Ma VWS, Tong M, et al. SCYL3, as a novel binding partner and regulator of ROCK2, promotes hepatocellular carcinoma progression. JHEP Rep. 2023;5:100604.","journal-title":"JHEP Rep"},{"key":"7804_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01270-x","volume":"19","author":"L Peng","year":"2020","unstructured":"Peng L, Sang H, Wei S, Li Y, Jin D, Zhu X, et al. circCUL2 regulates gastric cancer malignant transformation and cisplatin resistance by modulating autophagy activation via miR-142-3p\/ROCK2. Mol Cancer. 2020;19:156.","journal-title":"Mol Cancer"},{"key":"7804_CR19","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/onc.2016.249","volume":"36","author":"X Zhang","year":"2017","unstructured":"Zhang X, Zhang L, Du Y, Zheng H, Zhang P, Sun Y, et al. A novel FOXM1 isoform, FOXM1D, promotes epithelial-mesenchymal transition and metastasis through ROCKs activation in colorectal cancer. Oncogene. 2017;36:807\u201319.","journal-title":"Oncogene"},{"key":"7804_CR20","doi-asserted-by":"publisher","first-page":"5338","DOI":"10.1158\/0008-5472.CAN-11-2373","volume":"72","author":"D Vigil","year":"2012","unstructured":"Vigil D, Kim TY, Plachco A, Garton AJ, Castaldo L, Pachter JA, et al. ROCK1 and ROCK2 are required for non-small cell lung cancer anchorage-independent growth and invasion. Cancer Res. 2012;72:5338\u201347.","journal-title":"Cancer Res"},{"key":"7804_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13046-018-0683-9","volume":"37","author":"X Wang","year":"2018","unstructured":"Wang X, Sun D, Tai J, Chen S, Yu M, Ren D, et al. TFAP2C promotes stemness and chemotherapeutic resistance in colorectal cancer via inactivating Hippo signaling pathway. J Exp Clin Cancer Res. 2018;37:27.","journal-title":"J Exp Clin Cancer Res"},{"key":"7804_CR22","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.bbrc.2022.02.113","volume":"603","author":"Y Kaku","year":"2022","unstructured":"Kaku Y, Chiba K, Sato K, Onishi A, Ishida T, Okada K, et al. Protective effects of tadalafil against cisplatin-induced spermatogenic dysfunction. Biochem Biophys Res Commun. 2022;603:123\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"7804_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2019.111689","volume":"385","author":"X Deng","year":"2019","unstructured":"Deng X, Yi X, Deng J, Zou Y, Wang S, Shan W, et al. ROCK2 promotes osteosarcoma growth and metastasis by modifying PFKFB3 ubiquitination and degradation. Exp Cell Res. 2019;385:111689.","journal-title":"Exp Cell Res"},{"key":"7804_CR24","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17:557\u201388.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"7804_CR25","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s40265-020-01330-y","volume":"80","author":"SM Hoy","year":"2020","unstructured":"Hoy SM. Pemigatinib: first approval. Drugs. 2020;80:923\u20139.","journal-title":"Drugs"},{"key":"7804_CR26","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S1537-1891(03)00008-9","volume":"39","author":"B Wojciak-Stothard","year":"2002","unstructured":"Wojciak-Stothard B, Ridley AJ. Rho GTPases and the regulation of endothelial permeability. Vascul Pharm. 2002;39:187\u201399.","journal-title":"Vascul Pharm"},{"key":"7804_CR27","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3390\/cells9010132","volume":"9","author":"L Porter","year":"2020","unstructured":"Porter L, Minaisah RM, Ahmed S, Ali S, Norton R, Zhang Q, et al. SUN1\/2 are essential for RhoA\/ROCK-regulated actomyosin activity in isolated vascular smooth muscle cells. Cells. 2020;9:132.","journal-title":"Cells"},{"key":"7804_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112897","volume":"140","author":"M Yan","year":"2024","unstructured":"Yan M, Luo X, Han H, Qiu J, Ye Q, Zhang L, et al. ROCK2 increases drug resistance in acute myeloid leukemia via metabolic reprogramming and MAPK\/PI3K\/AKT signaling. Int Immunopharmacol. 2024;140:112897.","journal-title":"Int Immunopharmacol"},{"key":"7804_CR29","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jconrel.2024.03.041","volume":"369","author":"HY Tanaka","year":"2024","unstructured":"Tanaka HY, Nakazawa T, Miyazaki T, Cabral H, Masamune A, Kano MR. Targeting ROCK2 improves macromolecular permeability in a 3D fibrotic pancreatic cancer microenvironment model. J Control Release. 2024;369:283\u201395.","journal-title":"J Control Release"},{"key":"7804_CR30","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1186\/s13046-019-1385-7","volume":"38","author":"A Pranatharthi","year":"2019","unstructured":"Pranatharthi A, Thomas P, Udayashankar AH, Bhavani C, Suresh SB, Krishna S, et al. RhoC regulates radioresistance via crosstalk of ROCK2 with the DNA repair machinery in cervical cancer. J Exp Clin Cancer Res. 2019;38:392.","journal-title":"J Exp Clin Cancer Res"},{"key":"7804_CR31","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1146\/annurev-pathmechdis-012419-032711","volume":"15","author":"DC Chan","year":"2020","unstructured":"Chan DC. Mitochondrial dynamics and its involvement in disease. Annu Rev Pathol. 2020;15:235\u201359.","journal-title":"Annu Rev Pathol"},{"key":"7804_CR32","first-page":"25","volume":"9","author":"X Zeng","year":"2022","unstructured":"Zeng X, Zhang YD, Ma RY, Chen YJ, Xiang XM, Hou DY, et al. Activated Drp1 regulates p62-mediated autophagic flux and aggravates inflammation in cerebral ischemia-reperfusion via the ROS-RIP1\/RIP3-exosome axis. Mil Med Res. 2022;9:25.","journal-title":"Mil Med Res"},{"key":"7804_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2023.102739","volume":"63","author":"X Chang","year":"2023","unstructured":"Chang X, Niu S, Shang M, Li J, Guo M, Zhang W, et al. ROS-Drp1-mediated mitochondria fission contributes to hippocampal HT22 cell apoptosis induced by silver nanoparticles. Redox Biol. 2023;63:102739.","journal-title":"Redox Biol"},{"key":"7804_CR34","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41392-020-00216-5","volume":"5","author":"D Li","year":"2020","unstructured":"Li D, Li Y. The interaction between ferroptosis and lipid metabolism in cancer. Signal Transduct Target Ther. 2020;5:108.","journal-title":"Signal Transduct Target Ther"},{"key":"7804_CR35","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.tcb.2023.05.003","volume":"33","author":"LE Pope","year":"2023","unstructured":"Pope LE, Dixon SJ. Regulation of ferroptosis by lipid metabolism. Trends Cell Biol. 2023;33:1077\u201387.","journal-title":"Trends Cell Biol"},{"key":"7804_CR36","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1016\/j.cell.2022.06.003","volume":"185","author":"BR Stockwell","year":"2022","unstructured":"Stockwell BR. Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications. Cell. 2022;185:2401\u201321.","journal-title":"Cell"},{"key":"7804_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-2064-5","volume":"10","author":"E Park","year":"2019","unstructured":"Park E, Chung SW. ROS-mediated autophagy increases intracellular iron levels and ferroptosis by ferritin and transferrin receptor regulation. Cell Death Dis. 2019;10:822.","journal-title":"Cell Death Dis"},{"key":"7804_CR38","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41422-023-00788-1","volume":"33","author":"S Qiu","year":"2023","unstructured":"Qiu S, Zhong X, Meng X, Li S, Qian X, Lu H, et al. Mitochondria-localized cGAS suppresses ferroptosis to promote cancer progression. Cell Res. 2023;33:299\u2013311.","journal-title":"Cell Res"},{"key":"7804_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04997-1","volume":"13","author":"Z Miao","year":"2022","unstructured":"Miao Z, Tian W, Ye Y, Gu W, Bao Z, Xu L, et al. Hsp90 induces Acsl4-dependent glioma ferroptosis via dephosphorylating Ser637 at Drp1. Cell Death Dis. 2022;13:548.","journal-title":"Cell Death Dis"},{"key":"7804_CR40","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.freeradbiomed.2024.01.002","volume":"213","author":"L Ding","year":"2024","unstructured":"Ding L, Dang S, Sun M, Zhou D, Sun Y, Li E, et al. Quercetin induces ferroptosis in gastric cancer cells by targeting SLC1A5 and regulating the p-Camk2\/p-DRP1 and NRF2\/GPX4 axes. Free Radic Biol Med. 2024;213:150\u201363.","journal-title":"Free Radic Biol Med"},{"key":"7804_CR41","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.3390\/cancers16152621","volume":"16","author":"S Malla","year":"2024","unstructured":"Malla S, Nyinawabera A, Neupane R, Pathak R, Lee D, Abou-Dahech M, et al. Novel thienopyrimidine-hydrazinyl compounds induce DRP1-mediated non-apoptotic cell death in triple-negative breast cancer cells. Cancers. 2024;16:2621.","journal-title":"Cancers"},{"key":"7804_CR42","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.freeradbiomed.2023.12.034","volume":"212","author":"T Li","year":"2024","unstructured":"Li T, Huang HY, Qian B, Wang WH, Yuan Q, Zhang HY, et al. Interventing mitochondrial PD-L1 suppressed IFN-\u03b3-induced cancer stemness in hepatocellular carcinoma by sensitizing sorafenib-induced ferroptosis. Free Radic Biol Med. 2024;212:360\u201374.","journal-title":"Free Radic Biol Med"},{"key":"7804_CR43","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/s41392-022-01253-y","volume":"7","author":"Y Meng","year":"2022","unstructured":"Meng Y, Qiu L, Zeng X, Hu X, Zhang Y, Wan X, et al. Targeting CRL4 suppresses chemoresistant ovarian cancer growth by inducing mitophagy. Signal Transduct Target Ther. 2022;7:388.","journal-title":"Signal Transduct Target Ther"},{"key":"7804_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216802","volume":"588","author":"H Zhang","year":"2024","unstructured":"Zhang H, Wang H, Hu Y, Gao Y, Chen J, Meng Y, et al. Targeting PARP14 with lomitapide suppresses drug resistance through the activation of DRP1-induced mitophagy in multiple myeloma. Cancer Lett. 2024;588:216802.","journal-title":"Cancer Lett"},{"key":"7804_CR45","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1016\/j.yexcr.2012.04.017","volume":"318","author":"T Liu","year":"2012","unstructured":"Liu T, Yu X, Li G, Yuan R, Wang Q, Tang P, et al. Rock2 regulates Cdc25A through ubiquitin proteasome system in hepatocellular carcinoma cells. Exp Cell Res. 2012;318:1994\u20132003.","journal-title":"Exp Cell Res"},{"key":"7804_CR46","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.bbrc.2014.09.061","volume":"453","author":"D Huang","year":"2014","unstructured":"Huang D, Du X, Yuan R, Chen L, Liu T, Wen C, et al. Rock2 promotes the invasion and metastasis of hepatocellular carcinoma by modifying MMP2 ubiquitination and degradation. Biochem Biophys Res Commun. 2014;453:49\u201356.","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07804-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07804-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07804-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T20:02:50Z","timestamp":1751659370000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07804-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,4]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7804"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07804-9","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,4]]},"assertion":[{"value":"8 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Ethics and Research Committees of Jiangxi Cancer Hospital. The animal work was approved by the Animal Experimental Ethics Committee of Nanchang University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"493"}}